The base purchase price under the Asset Purchase Agreement was $450 million, subject to adjustment for net working capital as of the effective time and for finance lease obligations assumed by the buyer (as scheduled in the agreement), with any post-closing working capital adjustment to be determined within 90 days after closing. The agreement's closing conditions for the buyer included satisfaction of the seller's representations and warranties, receipt of required governmental approvals, issuability of title policies, absence of a material adverse change, and receipt of material third-party consents; the seller's conditions included satisfaction of the buyer's representations and warranties, receipt of governmental approvals, and absence of buyer insolvency. The agreement contemplated post-closing transition services agreements covering information technology, hospital and clinic operations, billing, and Medicare/Medicaid matters. No termination fee is disclosed in the filed agreement excerpts, and no legal advisors to either party are identified in the filings reviewed.

The transaction closed on April 1, 2026, as reported in a subsequent Form 8-K (Item 2.01) filed by Community Health Systems. At closing, the purchase price actually paid to CHS, after giving effect to estimated working capital and before transaction expenses, was $459 million in cash, subject to a further post-closing working capital adjustment. Leerink Partners served as exclusive financial advisor to Community Health Systems (the seller) on the transaction; no financial advisor to Huntsville Hospital Health System (the buyer) is identified in the filings.

Community Health Systems filed unaudited pro forma condensed consolidated financial statements reflecting the sale as if it had occurred on December 31, 2025 (balance sheet) and January 1, 2025 (income statement). On a pro forma basis, cash and cash equivalents would have increased by $450 million (the $459 million in proceeds net of $9 million of transaction expenses) to $710 million, and total assets would have increased from $13,204 million to $13,343 million. Total stockholders' deficit would have improved from $(1,159) million to $(1,021) million, reflecting a $138 million after-tax gain on the sale. The gain was calculated as $459 million of consideration received, less $9 million of transaction expenses, less a $136 million carrying value of the facility, and less $129 million of allocated goodwill, yielding a $185 million pretax gain ($138 million after a $47 million tax provision). For the year ended December 31, 2025, pro forma net operating revenues would have been reduced by $327 million and total operating costs and expenses by $483 million to reflect the elimination of the divested facility's results, while pro forma basic loss per share would have increased from $3.81 to $4.57 (diluted: $3.77 to $4.52), driven by the combination of eliminated operating income and the tax effects of the pro forma adjustments.

The company's subsequent quarterly disclosures (its first-quarter 2026 results press release) separately confirmed that of the hospitals divested by Community Health Systems during 2026 through that filing date, one group of facilities was completed effective April 1, 2026, which corresponds to the Crestwood transaction. No sector-specific synergy figures, exchange ratio, stock consideration, or financing/new debt details are disclosed in connection with this transaction, as it was an all-cash asset sale. No legal advisors for either Community Health Systems or Huntsville Hospital Health System are identified anywhere in the filings reviewed, and no termination fee was disclosed.